Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients

Charles Fogartya, Helen Hattersleyb, Lilla Di Scalac, Anton Drollmannac,*

a Spartanburg Medical Research, Spartanburg, SC, USA
b Novartis Horsham Research Centre, West Sussex, UK
c Novartis Pharma AG, Novartis Institutes for Biomedical Research, Translational Sciences, WSJ-210.6.30, CH-4002 Basel, Switzerland

Received 8 June 2010; accepted 29 October 2010
Available online 8 December 2010

KEYWORDS
NVA237; Long-acting muscarinic antagonist; COPD; 24-h bronchodilation; Efficacy

Summary
NVA237 is a novel, once daily inhaled long-acting muscarinic antagonist administered via a dry powder inhaler. This study aimed to assess the 24-h bronchodilatory effect following 14 days of treatment with inhaled NVA237 in patients with mild, moderate or severe COPD.

This was a randomized, double-blind, placebo-controlled, two-period, crossover, multicenter study. A total of 33 patients (≥40 years; smoking history of ≥10 pack-years) were randomized to receive NVA237 50 μg once daily followed by placebo or placebo followed by NVA237 50 μg for 14 days. Treatment periods were separated by a 7–14 day washout period. The primary variable was the mean forced expiratory volume in 1 s (FEV1) derived from the area under the curve (AUC) between 0 and 24 h post-dose on Day 14.

The 24-h FEV1 profiles showed a consistent bronchodilator effect for NVA237 versus placebo on Day 14. Least square (LS) mean difference in FEV1 AUC0–24 h values between NVA237 and placebo was 163 mL (P < 0.001). There were significant increases in mean FEV1 AUC0–12 h (LS mean difference 165 mL, P = 0.001) and FEV1 AUC12–24 h (161 mL, P < 0.001) versus placebo. NVA237 significantly improved peak FEV1 (by 208 mL, P < 0.001) and trough FEV1 (by 154 mL, P = 0.003) versus placebo on Day 14. NVA237 was well tolerated; all adverse events were mild or moderate in intensity and not related to study drug.

NVA237 50 μg once daily was well tolerated and showed significant and sustained 24-h bronchodilation in patients with COPD.

© 2010 Elsevier Ltd. All rights reserved.

Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. It is characterized by progressive airflow limitation that is not fully...
reversible in most patients. Guidelines have recognized that COPD is both preventable and treatable; however, it is frequently under-diagnosed and under-treated in clinical practice.1,2

Management of COPD requires individualized therapy to prevent and control symptoms, reduce the frequency and severity of exacerbations, and to improve exercise tolerance and quality of life.1 Treatment with bronchodilators is essential to the symptomatic management of COPD.1 Inhaled muscarinic antagonists, such as ipratropium and tiotropium bromide, are one of the main classes of bronchodilators used for the treatment of COPD. Short-acting ipratropium,1,4 and long-acting tiotropium5,6 have been shown to improve lung function and reduce COPD symptoms. Both agents are generally well tolerated in patients with COPD.1

NVA237 is a novel inhaled dry powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide. It is currently in development as a once daily bronchodilator for the treatment of COPD. Preclinical studies demonstrated that NVA237 has both high affinity for and slow dissociation from muscarinic receptors; an optimal profile for prolonged bronchodilation.7 NVA237 has a fast onset of effect and provides sustained 24-h bronchodilation. The safety and efficacy of NVA237 has been demonstrated in studies in patients with moderate-to-severe COPD.8,9 NVA237 is well tolerated at doses of up to 200 μg in this patient population.7 The results of a recent dose-ranging study indicate that 50 μg NVA237 provides bronchodilation that is both statistically significant and clinically relevant (pre-defined threshold exceeded, i.e. >120 mL). The magnitude of bronchodilation observed with 50 μg NVA237 is similar to that observed with open-label tiotropium 18 μg (131 mL versus 127 mL, respectively).8

While previous studies have shown that NVA237 has a fast onset of effect that is sustained over 24 h,8,9 a comprehensive 24-h bronchodilator profile of NVA237 has not been characterized to date. The present study in patients with mild, moderate or severe stable COPD was designed to assess the bronchodilatory effect of 50 μg NVA237 inhaled once daily compared with placebo, over 24-h interval following 14 day’s treatment.

Methods

Patients

Eligible patients were aged ≥40 years with stable mild, moderate or severe COPD according to the 2008 GOLD guidelines,10 and a smoking history of at least 10 pack-years. Patients were required to have post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% of the predicted normal value and post-bronchodilator FEV1/forced vital capacity (FVC) of <0.7 at Visit 1; FEV1 must increase by 5% or more following inhalation of ipratropium bromide in the bronchial reversibility test.

Patients were excluded if they required oxygen therapy on a daily basis for chronic hypoxemia, had a respiratory tract infection within 6 weeks prior to screening, or had been hospitalized for an exacerbation of airways disease in the 6 weeks before screening or during the screening period. Other exclusion criteria included: a history of asthma; prolonged heart-rate corrected QT interval (QTc) at screening or a history of QT syndrome; an untoward reaction to anti-cholinergics or contraindications for antimuscarinic agents; pregnancy or lactation; any other clinically relevant laboratory abnormality or clinically significant condition that might have compromised patient safety or compliance.

Medications for the treatment of COPD or allied conditions were not permitted during the study and were to be discontinued for an appropriate period prior to study screening. Patients requiring inhaled corticosteroids, cromoglycate, ketotifen or nedocromil had to be using a stable dose for at least one month prior to first study treatment. Patients were not enrolled if they were unable to use the Breezhaler® device, a single-dose dry powder inhaler (SDDPI), a pMDI (rescue medication) or perform spirometry measurements; were receiving b-blocker agents that were not highly b1 receptor-selective; or had received an investigational drug within 30 days or five half-lives prior to enrolment or dose administration. Women of child-bearing potential were excluded unless they were using appropriate contraception.

Study design

This was a randomized, double-blind, placebo-controlled, two-period, crossover, multicenter trial (ClinicalTrials.gov identifier: NCT00856193) with a treatment duration of 14 days per period. The study consisted of a screening period (performed between 21 and 2 days prior to first dose) and the two treatment periods separated by a washout phase of 7–14 days. Study medication was administered via the Breezhaler® device, a low-resistance SDDPI suitable for use by a wide range of patients with COPD.11 A study completion evaluation was performed on Day 15 of Period 2.

This study was conducted according to the ethical principles of the Declaration of Helsinki. The protocol was reviewed by the Independent Ethics Committee or Institutional Review Board for each participating centre. All patients provided written informed consent before enrolling in the study.

Study assessments and variables

Efficacy measurements were carried out on Day 1 (at 45 and 15 min pre-dose and at 5, 15 and 30 min and 1, 2, 3, 4 and 5 h post-dose), Day 7 (at 45 and 15 min pre-dose and at 5, 15 and 30 min and 1, 2, 3, 4, 5, 6, 10, 11.75, 23.25 and 23.75 h post-dose) and Day 14 (at 45 and 15 min pre-dose and at 5, 15 and 30 min and 1, 2, 3, 4, 5, 6, 10, 11.75, 13, 14, 20, 22, 23.25 and 23.75 h post-dose).

The primary efficacy variable was the standardized FEV1 area under the curve (AUC) between 0 and 24 h post-dose on Day 14. Secondary efficacy variables included AUC0–5 h, AUC0–12 h, and AUC12–24 h, for FEV1 on Day 14 (12 h was defined as the 11 h 45 min assessment), peak (defined as the highest value in the response profile on Day 1, 7 and 14, respectively) and trough FEV1 (defined as the mean of the 23 h 15 min and 23 h 45 min post-dose assessments), the standardized FEV1, AUC0–5 h, on Day 1 and AUC0–12 h, on Day 7. The home monitoring device (Pikometer) for FEV1 was used as a validation

a Breezhaler® is a registered trademark of Novartis Pharma AG, Basel, Switzerland.
test in this study. Profiles performed at home (Day 13) and while in the clinic (Day 14) were compared descriptively between treatment days (Day 13 versus Day 14) and with the ‘standard’ spirometry assessments (Pikometer versus spirometry) on Day 14.

Safety assessments included the incidence of all adverse events (AEs), serious adverse events (SAEs), with their severity and relationship to the study drug. In addition, changes in blood chemistry and hematology were monitored, and vital signs, physical condition and electrocardiograms (ECG) were regularly assessed throughout the study.

Statistical analyses

The crossover design of this study allowed the total number of patients analyzed to be kept to a minimum. A sample size of 26 patients was estimated to provide about 90% power to detect a clinically significant increase of 120 mL in standardized \( \text{AUC}_{0-24\ h} \) for FEV\(_1\) (24 h was defined as the 23 h 45 min assessment), assuming a two-sided significance level of 0.05 and standard deviation (SD) of 180 mL for within-patient differences. Originally, 32 patients were to be randomized to ensure approximately 26 completers.

All patients who completed at least one treatment period were included in the efficacy analysis. The primary efficacy analysis variable was standardized FEV\(_1\) \( \text{AUC}_{0-24\ h} \), following 14 days of treatment; the linear trapezoidal rule was used to calculate the AUC. Standardized FEV\(_1\) \( \text{AUC}_{0-24\ h} \) was analyzed with an analysis-of-covariance (ANCOVA) model, which included: treatment sequence, treatment and period as fixed factors, baseline FEV\(_1\) value as a covariate and patient as a random effect. The least square (LS) mean difference (with 95% confidence intervals) between NVA237 and placebo was estimated. Baseline was defined as the mean of the \(-45\) and \(-15\) min pre-dose values on Day 1 of each treatment period. Secondary efficacy variables were analyzed in a similar manner to the primary variable.

Safety assessments were conducted in the safety population, which included all patients who received at least one dose of study medication. Safety variables are summarized descriptively.

Results

Disposition and baseline characteristics

A total of 33 patients were enrolled into this study (Fig. 1). Two patients were withdrawn, one for abnormal test procedure results and one who was lost to follow-up. The majority of patients were male (66.7%) and Caucasian (93.9%). Other baseline demographic and clinical characteristics are shown in Table 1.

Efficacy

Primary efficacy variable

FEV\(_1\) \( \text{AUC}_{0-24\ h} \) values on Day 14 were significantly \( (P < 0.001) \) higher for NVA237 than for placebo; LS mean difference of 163 mL between NVA237 and placebo. Mean 24-h profiles of FEV\(_1\) on Day 14 (efficacy analysis set) are presented in Fig. 2.

Secondary efficacy variables

A summary of the statistical analysis of FEV\(_1\), AUC values assessed as secondary efficacy variables is provided in Table 2. FEV\(_1\) with NVA237 was significantly higher \( (P < 0.001) \) than placebo for all AUCs evaluated. On Day 14, there were significant increases in mean FEV\(_1\) \( \text{AUC}_{0-5\ h} \) (difference 198 mL, \( P < 0.001 \)), FEV\(_1\) \( \text{AUC}_{0-12\ h} \) (difference 165 mL, \( P = 0.001 \)) and FEV\(_1\) \( \text{AUC}_{12-24\ h} \) (161 mL, \( P < 0.001 \)) versus...
placebo. In addition, NVA237 increased mean FEV1 AUC0–12 h on Day 7 by 185 mL (\(P < 0.001\)) and mean FEV1 AUC0–5 h on Day 1 by 172 mL (\(P < 0.001\)) versus placebo.

All primary analyses for trough FEV1 comparisons showed a clinically significant effect (pre-defined threshold exceeded, i.e. >120 mL) at the 5% confidence level, except for the treatment LS mean difference in trough value for NVA237 on Day 7 (91 mL; 95% CI −0.011, 0.192). The difference in trough values between NVA237 and placebo on Day 14 was 154 mL (\(P = 0.003\)). A clinically significant effect was reported for all peak FEV1 comparisons. The mean difference in peak values between NVA237 and placebo was 208 mL (\(P < 0.001\)) on Day 14 and 173 mL (\(P = 0.011\)) on Day 7.

Safety

NVA237 was well tolerated. In total, five (15%) of the 33 patients experienced at least one AE (Table 3); three of these patients experienced an event only with placebo, one patient only with NVA237 and the fifth patient with both NVA237 and placebo. Almost all AEs observed in the study were of mild intensity; one AE of moderate intensity was reported: toothache (in the placebo group). No SAEs or severe events were reported. All AEs were transient in nature and not thought to be related to the study drug. There were no clinically relevant changes in hematological or biochemical measures during the study. In addition, there were no clinically relevant changes in vital signs or ECGs.

Discussion

The results of this study indicate that 50 μg NVA237 has a fast onset of effect, with a significant and sustained bronchodilatory effect over 24 h compared with placebo.

NVA237 significantly improved pulmonary function in patients with mild, moderate or severe stable COPD. The bronchodilatory effect was sustained for 24 h following 14 days of once daily treatment, as evidenced by significantly higher FEV1 AUC0–24 h values versus placebo (primary efficacy variable). The mean difference in FEV1 AUC0–24 h values between NVA237 and placebo was 163 mL (\(P < 0.001\)). Results obtained for secondary variables also showed that the efficacy of NVA237 was sustained over the full 24-h dosing interval, as indicated by the similar bronchodilatory response over the first (0–12 h) and second (12–24 h) fraction of the dosing interval. The bronchodilator effect of NVA237 once daily appears to be sustained for at least as long

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Day</th>
<th>Treatment</th>
<th>n</th>
<th>LS mean</th>
<th>SE</th>
<th>Contrast to placebo LS mean (95% CI)(^a)</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC0–5 h</td>
<td>1</td>
<td>Placebo</td>
<td>33</td>
<td>1.849</td>
<td>0.0235</td>
<td>0.172 (0.116, 0.228)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>NVA237</td>
<td>31</td>
<td>2.021</td>
<td>0.0242</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC0–12 h</td>
<td>14</td>
<td>Placebo</td>
<td>32</td>
<td>1.744</td>
<td>0.0340</td>
<td>0.198 (0.102, 0.294)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>NVA237</td>
<td>31</td>
<td>1.942</td>
<td>0.0346</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC12–24 h</td>
<td>7</td>
<td>Placebo</td>
<td>28</td>
<td>1.806</td>
<td>0.343</td>
<td>0.185 (0.088, 0.282)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>NVA237</td>
<td>31</td>
<td>1.991</td>
<td>0.0325</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>Placebo</td>
<td>32</td>
<td>1.714</td>
<td>0.0340</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>NVA237</td>
<td>31</td>
<td>1.879</td>
<td>0.0346</td>
<td>0.165 (0.073, 0.257)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>Placebo</td>
<td>32</td>
<td>1.615</td>
<td>0.0339</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>NVA237</td>
<td>31</td>
<td>1.776</td>
<td>0.0344</td>
<td>0.161 (0.079, 0.234)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

FEV1 = forced expiratory volume in 1 s; AUC = area under curve; LS = least square; SE = standard error; CI = confidence interval. \(^a\) adjusted for baseline covariate.
as tiotropium.\textsuperscript{12} Van Noord et al. (2005) showed that tiotropium 18 μg once daily for 6 weeks increased mean FEV\textsubscript{1} AUC by 127 mL from baseline during the first 12 h post-dose, and by 43 mL 12–24 h post-dose. In comparison with ipratropium bromide, the bronchodilator effect of NVA237 once daily is sustained for longer; ipratropium bromide has a 6 h duration of action, thereby necessitating four times daily administration to maintain efficacy over 24 h.\textsuperscript{13}

While the results of this study clearly demonstrate that NVA237 provides significant sustained 24-h bronchodilation, moderate fluctuations in the effects of NVA237 versus placebo on Day 14 are apparent within the dosing interval. These fluctuations may be caused by the methodological variability of spirometry. Physiological fluctuations of bronchomotor tone, and thus expiratory flow, over the day could also have influenced the results; activity of the sympathetic system is postulated to be more prominent in the day, whereas parasympathetic system activity is increased during the night.\textsuperscript{14–16}

Previously it has been postulated that receptor binding kinetics, in combination with in vivo models in dogs, may be predictive of the differences in duration of action of inhaled antimuscarinic compounds.\textsuperscript{17} In these settings there were differences in the receptor dissolution and duration of action between tiotropium and NVA237. The missing link to the observations in clinical studies may be related to the fact that receptor binding kinetics are only one fractional part of compound pharmacology and can therefore not reliably predict the duration of action of a compound administered to the lung. Experimental in vitro settings should try to better approximate physiological conditions and utilise formulations that are representative of those used in the clinic. Clinical data of NVA237 show similar response profiles compared with tiotropium up to 24 h after dosing. The dose response pattern of NVA237 appeared to be in the same dose order early after dosing as well at 24 h after dosing, making it unlikely that the 24 h duration of action is achieved by using an unnecessarily high dose.\textsuperscript{8} The clinical data presented in this paper shows that NVA237 is effective 24 h post-dose and confirms the results of previous studies in patients with COPD.\textsuperscript{8,9}

NVA237 improved all other FEV\textsubscript{1} AUC values analyzed compared with placebo. On Day 14, mean FEV\textsubscript{1}, AUC\textsubscript{0–5 h} increased by 198 mL (P < 0.001). In addition, mean FEV\textsubscript{1}, AUC\textsubscript{0–5 h} on Day 1 increased by 172 mL (P < 0.001). This result provides further evidence that NVA237 has a fast onset of effect, and suggests that patients may experience rapid relief from symptoms of dyspnea after starting treatment. Peak and trough FEV\textsubscript{1} were assessed on Day 7 and Day 14 of the study. Treatment with NVA237 was associated with a consistent, statistically significant effect versus placebo on peak FEV\textsubscript{1} values on both days. Trough values on Day 14 were also significantly greater in NVA237-treated patients. The effect on trough FEV\textsubscript{1} values was in the range of that observed with the clinical use of tiotropium and ipratropium bromide.\textsuperscript{6,13,18}

Overall, the results of this study are consistent with previous findings that once daily NVA237 provides sustained 24-h bronchodilation with a fast onset of effect.\textsuperscript{8,9}

NVA237 was well tolerated. Only two patients experienced AEs while receiving NVA237; all were mild and not related to the study drug. In addition, local anti-cholinergic side effects, such as dry mouth which has been reported in 15–16% of patients taking tiotropium,\textsuperscript{6,13} were not observed in the present study. This might be due to the short treatment duration of this study, as a median time of onset of dry mouth of 4 weeks has previously been reported with ipratropium and tiotropium.\textsuperscript{5} Overall, the safety results are consistent with previous findings demonstrating the good safety profile of NVA237.\textsuperscript{8,9}

In summary, compared with placebo, NVA237 50 μg showed significant and sustained bronchodilatory efficacy in patients with mild, moderate or severe COPD, and was well tolerated. The results of the present study provide additional evidence to support the continued development of once daily NVA237 for the treatment of COPD.

Acknowledgements

The principal study investigators were: Dr C Fogarty, Dr S de la Motte and Dr Z Kobalava. Editorial assistance was provided by Melanie Stephens, ACUMED, UK. This assistance was funded by Novartis Pharma AG, Basel, Switzerland.

Conflict of interest statement

Dr Fogarty has received speakers honoraria from Novartis. Helen Hattersley, Lilla Di Scala and Anton Drollmann are all employees of Novartis Pharmaceuticals.

Role of funding source

This study was sponsored by Novartis Pharma AG, Basel, Switzerland, who had involvement in the study design, the collection, analysis and interpretation of data, writing of the study report and the decision to submit the manuscript for publication.

References


